<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00192</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Manufacturer Determination.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Manufacturers shall  <!-- PJG 0012 frnewline --> determine whether the information gathered pursuant to the  <!-- PJG 0012 frnewline --> literature search in &sect;79.52(d) contains the results of  <!-- PJG 0012 frnewline --> adequately performed and adequately documented previous testing  <!-- PJG 0012 frnewline --> which provides information reasonably comparable to that supplied  <!-- PJG 0012 frnewline --> by the health tests described in &sect;&sect;79.62 through 79.68 regarding  <!-- PJG 0012 frnewline --> the carcinogenicity, mutagenicity, neurotoxicity, teratogenicity,  <!-- PJG 0012 frnewline --> reproductive/fertility measures, and general toxicity effects of  <!-- PJG 0012 frnewline --> the emissions of the fuel or additive. When manufacturers make  <!-- PJG 0012 frnewline --> an affirmative determination, they need submit only the  <!-- PJG 0012 frnewline --> information gathered pursuant to &sect;79.52(d) for such tests. EPA  <!-- PJG 0012 frnewline --> maintains final authority in judging whether the information is  <!-- PJG 0012 frnewline --> an adequate substitution in lieu of conducting the associated  <!-- PJG 0012 frnewline --> tests. EPA's determination of the adequacy of existing  <!-- PJG 0012 frnewline --> information shall be guided by the considerations described in  <!-- PJG 0012 frnewline --> paragraph (d) of this section. If EPA finds that the  <!-- PJG 0012 frnewline --> manufacturer has relied upon inadequate test data, then the  <!-- PJG 0012 frnewline --> manufacturer will not be considered to be in compliance until the  <!-- PJG 0012 frnewline --> corresponding tests have been conducted and the results submitted  <!-- PJG 0012 frnewline --> to EPA.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (c)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Testing.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1) All testing required pursuant to this section must be done in accordance with the procedures, equipment, and facility  <!-- PJG 0012 frnewline --> requirements described in &sect;&sect;79.57, 79.60, and 79.61 regarding  <!-- PJG 0012 frnewline --> emissions generation, good laboratory practices, and inhalation  <!-- PJG 0012 frnewline --> exposure testing, respectively, as well as any other requirements  <!-- PJG 0012 frnewline --> described in this subpart. The laboratory conducting the animal  <!-- PJG 0012 frnewline --> studies shall be registered and in good standing with the United  <!-- PJG 0012 frnewline --> States Department of Agriculture and regularly inspected by  <!-- PJG 0012 frnewline --> United States Department of Agriculture veterinarians. In  <!-- PJG 0012 frnewline --> addition, the facility must be accredited by a generally  <!-- PJG 0012 frnewline --> recognized independent organization which sets laboratory animal  <!-- PJG 0012 frnewline --> care standards. Use of inadequate test protocols or substandard  <!-- PJG 0012 frnewline --> laboratory techniques in performing any testing required by this  <!-- PJG 0012 frnewline --> subpart may result in cancellation of all affected registrations.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) Carcinogenic or mutagenic effects in animals from  <!-- PJG 0012 frnewline --> emissions exposures shall be determined pursuant to &sect;79.64  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> In  <!-- PJG 0012 frnewline --> vivo <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Micronucleus Assay, &sect;79.65  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> In vivo <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Sister Chromatid  <!-- PJG 0012 frnewline --> Exchange Assay, and &sect;79.68  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Salmonella typhimurium <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Reverse  <!-- PJG 0012 frnewline --> Mutation Assay. Teratogenic effects and reproductive toxicity  <!-- PJG 0012 frnewline --> shall be examined pursuant to &sect;79.63 Fertility  <!-- PJG 0012 frnewline --> Assessment/Teratology. General toxicity and pulmonary effects  <!-- PJG 0012 frnewline --> shall be determined pursuant to &sect;79.62 Subchronic Toxicity Study  <!-- PJG 0012 frnewline --> with Specific Health Effect Assessments. Neurotoxic effects  <!-- PJG 0012 frnewline --> shall be determined pursuant to &sect;79.66 Neuropathology Assessment  <!-- PJG 0012 frnewline --> and &sect;79.67 Glial Fibrillary Acidic Protein Assay.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> EPA Determination. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (1) After submission of all information and testing, EPA in its judgment shall determine whether previously conducted tests relied upon in the registration submission are adequately  <!-- PJG 0012 frnewline --> performed and documented and provide information reasonably  <!-- PJG 0012 frnewline --> comparable to that which would be provided by the tests described  <!-- PJG 0012 frnewline --> herein. Manufacturers' submissions shall be sufficiently  <!-- PJG 0012 frnewline --> detailed to allow EPA to judge the adequacy of protocols,  <!-- PJG 0012 frnewline --> techniques, experimental design, statistical analyses, and  <!-- PJG 0012 frnewline --> conclusions. Studies shall be performed using generally accepted  <!-- PJG 0012 frnewline --> scientific principles, good laboratory techniques, and the  <!-- PJG 0012 frnewline --> testing guidelines specified in these regulations.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (2) EPA shall give appropriate weight when making this  <!-- PJG 0012 frnewline --> determination to the following factors:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (i) The age of the data;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (ii) The adequacy of documentation of procedures, findings,  <!-- PJG 0012 frnewline --> and conclusions;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (iii) The extent to which the testing conforms to generally  <!-- PJG 0012 frnewline --> accepted scientific principles and practices;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (iv) The type and number of test subjects;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (v) The number and adequacy of exposure concentrations,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> i.e. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , emission dilutions;  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (vi) The degree to which the tested emissions were  <!-- PJG 0012 frnewline --> generated by procedures and under conditions reasonably  <!-- PJG 0012 frnewline --> comparable to those set forth in &sect;79.57; and  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            